Previous close | 8.17 |
Open | 8.39 |
Bid | 7.30 x 900 |
Ask | 10.85 x 800 |
Day's range | 8.15 - 8.92 |
52-week range | 3.67 - 9.50 |
Volume | |
Avg. volume | 12,412 |
Market cap | 69.376M |
Beta (5Y monthly) | 0.56 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 01 Sept 2022 |
1y target est | N/A |
OLDSMAR, Fla., April 15, 2024--Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the "Company"), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 29, 2024.
OLDSMAR, Fla., March 25, 2024--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company" or "Cryo-Cell"), the world’s first private cord blood bank to separate and store stem cells in 1992, today announced that its Board of Directors has authorized the spin-off of its newly formed subsidiary, Celle Corp., to the Cryo-Cell shareholders and to explore all strategic alternatives for Cryo-Cell (post spin-off) to maximize shareholder value, including, but not limited to, equity and/or de
OLDSMAR, Fla., February 28, 2024--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2023.